[Pharmacological properties and individualized selection of CGRP inhibitors for migraine prevention and acute treatment].

This article reviews the use of CGRP inhibitors for migraine treatment. These include monoclonal antibodies and small-molecule receptor antagonists. Monoclonal antibodies like erenumab and fremanezumab have proven effective. They help reduce migraine frequency and improve daily functioning. Small-molecule drugs like ubrogepant and rimegepant also show promise. They can provide quick relief when taken early during an attack. These medications have fewer side effects compared to traditional treatments. Patients experience less need for other pain medications. The article discusses how these drugs work and their dosing. It emphasizes the importance of personalized treatment plans for migraine patients. Choosing the right medication can lead to better outcomes. Overall, CGRP inhibitors represent a significant advancement in migraine management. They offer hope for many who suffer from this debilitating condition. Understanding their properties can help doctors make informed treatment decisions. Clinical relevance: This research highlights the effectiveness of CGRP inhibitors, offering new options for migraine patients.